[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586069":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":23,"studyPopulation":23,"armGroups":33,"interventions":46,"overallOfficials":23,"centralContacts":23,"locations":56,"responsibleParty":73,"collaborators":23,"id":75,"slug":23,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":23,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":23,"maxAge":23,"enrollmentInfo":82,"targetDuration":23,"studyType":85,"phases":86,"briefSummary":89,"conditions":90,"keywords":23,"overallStatus":59,"whyStopped":23,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"British University In Egypt","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"Pain intensity","Visual Analog Scale (0-10), which measured a range of \"no pain\" to \"unbearable pain\" on a 100 mm horizontal line \\[10\\]. to determine the intensity of pain on day 0, day 3, day 5, day 7, and day 10","10 days",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"Size of ulcers (in mm)","after starting treatment, ulcer size was recorded on day 0, day 3, day 5, day 7, and day 10 using a calibrated dental probe with millimeter marking",{"measure":18,"description":19,"timeFrame":12},"Complete healing duration","the duration till complete healing is achieved is recorded in days",{"measure":21,"description":22,"timeFrame":12},"OHIP-14","has been assessed 1 week after intervention. OHIP-14 utilizes a scale with five categories (1 = never, 2 = hardly ever, 3 = occasionally, 4 = fairly often, and 5 = very often). A lower score in any of the five categories indicates higher satisfaction",null,{"allocation":25,"interventionModel":26,"interventionModelDescription":23,"primaryPurpose":27,"observationalModel":23,"timePerspective":23,"maskingInfo":28},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":29,"maskingDescription":23,"whoMasked":30},"DOUBLE",[31,32],"PARTICIPANT","OUTCOMES_ASSESSOR",[34,40],{"label":35,"type":36,"description":37,"interventionNames":38},"control","ACTIVE_COMPARATOR","15 patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.",[39],"Drug: topical application of Triamcinolone acetonide gel",{"label":41,"type":42,"description":43,"interventionNames":44},"Oxygenated gel Group","EXPERIMENTAL","15 patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days",[45],"Drug: topical application of oxygenated gel",[47,52],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":23},"DRUG","topical application of oxygenated gel","patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days",[41],{"type":48,"name":53,"description":54,"armGroupLabels":55,"otherNames":23},"topical application of Triamcinolone acetonide gel","patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.",[35],[57],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":23,"geoPoint":23,"contacts":65},"British University in Egypt","RECRUITING","Al Sherouk City","Cairo Governorate","11837","Egypt","EG",[66,71],{"name":67,"role":68,"phone":69,"phoneExt":23,"email":70},"ahmed hamdy, phd","CONTACT","+201061112512","ahmed.esmaail@bue.edu.eg",{"name":72,"role":68,"phone":23,"phoneExt":23,"email":23},"Hamdy",{"type":74,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100586069",false,"NCT06910579","Oxygenated Gel Therapy in the Management of Oral Aphthous Ulcers","Efficacy of Oxygenated Gel Therapy in the Management of Oral Aphthous Ulcers: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Clinically diagnosed patients with chronic aphthous stomatitis measuring ≤6 mm in size in the oral cavity and who gave written consent for participation.\n* Only single ulcers were considered for the study.\n* Systemically healthy patients.\n\nExclusion Criteria:\n\n* The study excluded patients with a history of associated systemic disease.\n* Cases of chronic aphthous stomatitis (major), lesions of herpetic form, numerous aphthae, and smoking.\n* Patients with a history of hypersensitivity to the used agents.\n* Pregnancy and lactation","ALL",{"count":83,"type":84},30,"ESTIMATED","INTERVENTIONAL",[87,88],"PHASE2","PHASE3","Interventions of both groups:\n\nOxygenated gel Group: 15 patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days.\n\nTriamcinolone acetonide Group: 15 patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.\n\nPatients in both groups were reexamined after treatment at different intervals (day 3, day 5, day 7, and day 10).",[91],"Aphthus Ulcer","2025-09-16",{"date":94,"type":95},"2025-09-18","ACTUAL",{"date":97,"type":95},"2025-03-15",{"date":99,"type":84},"2026-04-12",{"name":5,"class":6},1]